CA
NZ
UK
AU
IND
US
IRIDEX Corporation (NASDAQ:IRIX), a maker of laser systems for treating eye disease, reported encouraging signs in its glaucomaBusinessand a return to positive operating cash flow, even as overall revenue softened. The question for investors is whether the higher-growth glaucomaFranchiseand improving cost discipline can offset …
AdaptHealth (NASDAQ:AHCO), a provider of home medical equipment and healthcare-at-home services, posted strong revenue growth in its latest quarter, but a fuller look at the results shows that growth was overshadowed by a goodwill impairment,Marginpressure and a sharply lowered profit outlook. The question of …
Dare Bioscience (NASDAQ:DARE), a biotechnology company focused on women's health, faces acuteLiquidityconcerns even as its lead contraceptive program delivered encouraging pivotal-trial data and it began transitioning toward a commercial-stage business. The tension between clinical progress and financial strain frames the central question for the …
MiMedx Group (NASDAQ:MDXG), a maker of regenerative-medicine products derived from placental tissue, is grappling with a major Medicare reimbursement change that has sharply reduced its wound-care revenue, even as its surgical business continues to grow. The company's near-term outlook must be weighed against this …
Artivion (NYSE:AORT), a maker of medical devices for cardiac and vascular surgery, reported solid revenue growth, strong product momentum, a key FDA approval and a strategic acquisition. For investors, the combination of double-digit growth and pipeline expansion raises the question of whether the company …
Valion Bio, Inc. (NASDAQ: VBIO) has a reported 9.9% beneficial ownership position from 3i, LP, representing 3,334,139 shares. The percentage is calculated against 32,140,634 common shares outstanding as of August 24, 2026. The position is reported through an amended Schedule 13D.
MediWound Ltd. (NASDAQ: MDWD) has a beneficial ownership position of 1,348,323 common shares held by HOLD Alapkezelo Zrt. Representing approximately 10.4% of MediWound’s common stock. The position is identified as passive, with the holder stating that the securities were not acquired or held to …
Valion Bio, Inc. (NASDAQ: VBIO) has a reported 9.9% beneficial ownership position from 3i, LP, representing 3,334,139 shares. The percentage is calculated against 32,140,634 common shares outstanding as of August 24, 2026. The position is reported through an amended Schedule 13D.
HUTCHMED (China) Limited received conditional approval from China’s National Medical Products Administration for ATLED, its oral fanregratinib treatment for a defined group of adult intrahepatic cholangiocarcinoma patients. The decision covers advanced, metastatic or unresectable disease with FGFR2 fusions or rearrangements after prior systemic therapy. …
Each ADS represents 500 ordinary shares. The pre-funded warrant exercise price is $0.0001 per ADS, meaning KAZIA THERAPEUTICS LTD (NASDAQ: KZIA) expects little additional cash from those exercises.
Please wait processing your request...